Artivion Reports Third Quarter 2022 Financial Results

Rhea-AI Summary

Artivion, Inc. (NYSE: AORT) reported third-quarter 2022 revenue of $76.8 million, marking a 6% increase on a GAAP basis compared to Q3 2021. Non-GAAP constant currency revenue grew by 11%. Notable growth came from On-X, with a 17% GAAP and 19% non-GAAP increase. Internationally, revenue rose by 25% in Asia Pacific and 22% in Latin America. However, the company faced a net loss of $13.7 million compared to a profit in the prior year. The revenue outlook for 2022 has been narrowed to $313.0-$316.0 million, projecting 9%-10% growth. The company also anticipates FDA approvals for key products by year-end.

Positive

• Revenue of $76.8 million, a 6% increase YoY on GAAP basis.
• Non-GAAP constant currency revenue growth of 11%.
• On-X revenue grew 17% on GAAP basis and 19% on non-GAAP basis.
• International revenue growth of 25% in Asia Pacific and 22% in Latin America.
• Continued momentum in product pipeline and anticipated FDA approvals.

Negative

• Net loss of $13.7 million in Q3 2022 vs. net income of $10.6 million in Q3 2021.
• Non-GAAP net loss of $1.9 million compared to $1.2 million in Q3 2021.
• Included pretax losses of $3.7 million related to foreign currency revaluation.

Third Quarter and Recent Business Highlights:

• Achieved revenue of $76.8 million in the third quarter of 2022 versus $72.2 million in the third quarter of 2021, an increase of 6% on a GAAP basis and 11% on a non-GAAP constant currency basis
• On-X revenues increased 17% on a GAAP basis and 19% on a non-GAAP constant currency basis in the third quarter of 2022 compared to the third quarter of 2021

ATLANTA, Nov. 3, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the third quarter ended September 30, 2022.

"We remain well positioned to deliver on our growth strategy, particularly given the continued fundamental strength of our business. During the third quarter we made substantial progress on each of our key three-year strategic growth initiatives delivering year-over-year total revenue growth of 6% on a GAAP basis and 11% on a non-GAAP constant currency basis. These results were driven by growth across all four of our major product lines, including 19% growth in On-X revenue and 13% growth in tissue processing, both on a constant currency basis. Internationally, we delivered 25% revenue growth in Asia Pacific and 22% revenue growth in Latin America, both on a constant currency basis, driven by the continued expansion of our commercial footprint and securement of additional regulatory approvals. Our third quarter performance continues the momentum we have built throughout the year, resulting in a constant currency revenue growth of 11% year-over-year for the first nine months of 2022. We expect continued strong performance through the remainder of the year as we remain focused on executing on our key objectives," said Pat Mackin, Chairman, President, and Chief Executive Officer.

Mr. Mackin added, "We also made good progress in advancing our product pipeline, which is expected to drive growth in both the near and long term. We continue to anticipate FDA PMA approval for PROACT Mitral and for PerClot by year end. Meanwhile, we continue to make progress on patient enrollment in the PERSEVERE trial to secure FDA approval for AMDS, a simple, elegant stent graft solution to treat aortic arch disease. Taken as a whole, we continue to see meaningful opportunities to grow our total addressable market through pipeline development as well as to maintain momentum with our existing portfolio in our current markets."

Third Quarter 2022 Financial Results
Total revenues for the third quarter of 2022 were $76.8 million, reflecting an increase of 6% on a GAAP basis and 11% on a non-GAAP constant currency basis, both compared to the third quarter of 2021.

R&D expenses for the third quarter of 2022 include a $4.7 million charge for estimated costs associated with the termination and wind-down of the PROACT Xa study as recommended by the Data and Safety Monitoring Board ("DSMB").  The majority of these costs include future administrative costs that will be incurred during the fourth quarter of 2022 and the first quarter of 2023, as well as the estimated cost of clinical drugs purchased for patients participating in the study and not expected to be recovered.  These costs are non-recurring and have been excluded for purposes of calculating adjusted EBITDA and non-GAAP earnings per share.

Net loss for the third quarter of 2022 was ($13.7) million, or ($0.34) per fully diluted common share, compared to net income of $10.6 million, or $0.26 per fully diluted common share for the third quarter of 2021. Non-GAAP net loss for the third quarter of 2022 was ($1.9) million, or ($0.05) per fully diluted common share, compared to non-GAAP net loss of ($1.2) million, or ($0.03) per fully diluted common share for the third quarter of 2021. Net loss in the third quarter of 2022 includes pretax losses related to foreign currency revaluation of $3.7 million.

2022 Financial Outlook
Artivion is narrowing its constant currency revenue growth to between 9% and 10% for the full year of 2022 compared to 2021.  With the continued appreciation of the dollar versus other major currencies, full year revenues are now expected to be between $313.0 million and $316.0 million.

The Company's financial performance for 2022 and future periods is subject to the risks identified below.

Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, including non-GAAP revenue, non-GAAP net income, non-GAAP EBITDA, and non-GAAP general, administrative, and marketing expenses. Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with US GAAP. In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies. The Company's non-GAAP revenues are adjusted for the impact of changes in currency exchange. The Company's non-GAAP net income; non-GAAP EBITDA; and non-GAAP general, administrative, and marketing results exclude (as applicable) depreciation and amortization expense; interest income and expense; stock-based compensation expense; loss or gain on foreign currency revaluation; expenses related to the DSMB recommended termination of the PROACT Xa clinical trial; income tax expense or benefit; corporate rebranding expense; business development, integration, and severance income or expense; non-cash interest expense; and gain from sale of non-financial assets. The Company generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Company management believes that these non-GAAP presentations provide useful information to investors regarding unusual non-operating transactions; the operating expense structure of the Company's existing and recently acquired operations, without regard to its on-going efforts to acquire additional complementary products and businesses, and the transaction and integration expenses incurred in connection with recently acquired and divested product lines; and the operating expense structure excluding fluctuations resulting from foreign currency revaluation and stock-based compensation expense. The Company believes it is useful to exclude certain expenses because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods as a result of factors such as impact of recent acquisitions, non-cash expense related to amortization of previously acquired tangible and intangible assets, and any related adjustments to their carrying values. The Company has adjusted for the impact of changes in currency exchange from certain revenues to evaluate comparable product growth rates on a constant currency basis. The Company does, however, expect to incur similar types of expenses and currency exchange impacts in the future, and this non-GAAP financial information should not be viewed as a statement or indication that these types of expenses will not recur. Company management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety, including the reconciliation of GAAP to non-GAAP financial measures."

Webcast and Conference Call Information
The Company will hold a teleconference call and live webcast later today, November 3, 2022, at 4:30 p.m. ET to discuss the results, followed by a question and answer session. To participate in the conference call dial 862-298-0702 a few minutes prior to 4:30 p.m. ET. The teleconference replay will be available approximately one hour following the completion of the event and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13733812.

The live webcast and replay can be accessed by going to the Investors section of the Artivion website at www.Artivion.com and selecting the heading Webcasts & Presentations.

About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.

Forward Looking Statements
Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our beliefs that we expect our strong momentum to continue through the remainder of the year as we remain focused on executing on our key objectives; our product pipeline is expected to drive growth in both the near and long term; we believe there are meaningful opportunities to grow our total addressable market through pipeline development as well as to maintain momentum with our existing portfolio in our current markets; we continue to anticipate FDA PMA approval for PROACT Mitral and for PerClot this year; and we will deliver year-over-year constant currency revenue growth of 9-10% in 2022 versus 2021. These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations, including that the benefits anticipated from the Ascyrus Medical LLC transaction and Endospan agreements may not be achieved; the benefits anticipated from our clinical trials may not be achieved or achieved on our anticipated timeline; our products may not be able to consistently retain their existing regulatory approvals or special regulatory approvals in order to be commercialized; products in our pipeline may not receive regulatory approval at all or receive regulatory approval on our anticipated timelines; our products that obtain regulatory approval may not be adopted by the market as much as we anticipate or at all;  and the continued effects of COVID-19, including new COVID-19 variants, and continued hospital staffing shortages and macroeconomic factors such as inflation and currency exchange could adversely impact our results.  These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2021. Artivion does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise.

 

Artivion, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income In Thousands, Except Per Share Data (Unaudited)
	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Revenues:
Products	$           55,248		$           53,107		$         171,726		$         162,528
Preservation services	21,590		19,100		62,665		56,914
Total revenues	76,838		72,207		234,391		219,442
Cost of products and preservation services:
Products	17,743		15,503		53,381		46,592
Preservation services	10,351		8,915		29,375		26,710
Total cost of products and preservation services	28,094		24,418		82,756		73,302
Gross margin	48,744		47,789		151,635		146,140
Operating expenses:
General, administrative, and marketing	41,051		39,053		118,989		118,521
Research and development	11,799		9,972		30,575		26,086
Total operating expenses	52,850		49,025		149,564		144,607
Gain from sale of non-financial assets	—		(15,923)		$                   —		(15,923)
Operating (loss) income	(4,106)		14,687		2,071		17,456
Interest expense	4,805		4,100		12,854		12,995
Interest income	(40)		(18)		(86)		(60)
Other expense, net	3,661		2,661		7,564		3,261
(Loss) income before income taxes	(12,532)		7,944		(18,261)		1,260
Income tax expense (benefit)	1,181		(2,638)		3,100		(4,006)
Net (loss) income	$          (13,713)		$           10,582		$          (21,361)		$              5,266
(Loss) income per share:
Basic	$              (0.34)		$                0.27		$              (0.53)		$                0.13
Diluted	$              (0.34)		$                0.26		$              (0.53)		$                0.13
Weighted-average common shares outstanding:
Basic	40,115		39,086		39,999		38,924
Diluted	40,115		44,453		39,999		39,496
Net (loss) income	$          (13,713)		$           10,582		$          (21,361)		$              5,266
Other comprehensive loss:
Foreign currency translation adjustments	(16,895)		(5,010)		(35,466)		(12,327)
Comprehensive (loss) income	$          (30,608)		$              5,572		$          (56,827)		$            (7,061)

 

Artivion, Inc. and Subsidiaries Condensed Consolidated Balance Sheets In Thousands
	September 30, 2022		December 31, 2021
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$             37,572		$             55,010
Trade receivables, net	57,159		53,019
Other receivables	7,880		5,086
Inventories, net	73,044		76,971
Deferred preservation costs, net	45,483		42,863
Prepaid expenses and other	16,851		14,748
Total current assets	237,989		247,697
Goodwill	234,773		250,000
Acquired technology, net	148,060		166,994
Operating lease right-of-use assets, net	41,320		45,714
Property and equipment, net	36,286		37,521
Other intangibles, net	31,112		34,502
Deferred income taxes	6,103		2,357
Other assets	7,088		8,267
Total assets	$           742,731		$           793,052
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable	$             10,721		$             10,395
Accrued compensation	11,079		13,163
Accrued expenses	10,088		7,687
Taxes payable	5,293		3,634
Accrued procurement fees	2,302		3,689
Current maturities of operating leases	3,061		3,149
Current portion of long-term debt	1,562		1,630
Other liabilities	1,886		1,606
Total current liabilities	45,992		44,953
Long-term debt	306,674		307,493
Contingent consideration	44,800		49,400
Non-current maturities of operating leases	40,915		44,869
Non-current finance lease obligation	3,450		4,374
Deferred income taxes	34,058		28,799
Deferred compensation liability	5,082		5,952
Other liabilities	6,652		6,484
Total liabilities	$           487,623		$           492,324
Commitments and contingencies
Shareholders' equity:
Preferred stock	—		—
Common stock (issued shares of 41,816 in 2022 and 41,397 in 2021)	418		414
Additional paid-in capital	334,077		322,874
Retained (deficit) earnings	(19,386)		1,975
Accumulated other comprehensive loss	(45,353)		(9,887)
Treasury stock, at cost, 1,487 shares as of September 30, 2022 and December 31, 2021	(14,648)		(14,648)
Total shareholders' equity	255,108		300,728
Total liabilities and shareholders' equity	$           742,731		$           793,052

 

Artivion, Inc. and Subsidiaries Condensed Consolidated Statement of Cash Flows In Thousands (Unaudited)
	Nine Months Ended September 30,
	2022		2021
Net cash flows from operating activities:
Net (loss) income	$          (21,361)		$              5,266
Adjustments to reconcile net (loss) income to net cash from operating activities:
Depreciation and amortization	17,016		18,008
Non-cash compensation	9,189		7,471
Non-cash lease expense	5,656		5,566
Deferred income taxes	5,097		(8,128)
Write-down of inventories and deferred preservation costs	3,116		3,987
Non-cash interest expense	1,372		2,025
Change in fair value of contingent consideration	(4,600)		4,970
Gain from sale of non-financial assets	—		(15,923)
Other	151		678
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(1,788)		(2,268)
Accounts payable, accrued expenses, and other liabilities	(2,103)		65
Inventories and deferred preservation costs	(5,781)		(16,986)
Receivables	(10,900)		(8,032)
Net cash flows used in operating activities	(4,936)		(3,301)
Net cash flows from investing activities:
Acquisition of intangible assets	(1,123)		(726)
Capital expenditures	(6,924)		(10,524)
Proceeds from sale of non-financial assets, net	—		19,000
Other	—		722
Net cash flows (used in) provided by investing activities	(8,047)		8,472
Net cash flows from financing activities:
Proceeds from exercise of stock options and issuance of common stock	3,344		3,531
Redemption and repurchase of stock to cover tax withholdings	(1,791)		(1,898)
Repayment of term loan	(2,033)		(2,397)
Payment of debt issuance costs	—		(2,219)
Other	(300)		(439)
Net cash flows used in financing activities	(780)		(3,422)
Effect of exchange rate changes on cash and cash equivalents	(3,675)		1,418
(Decrease) increase in cash and cash equivalents	(17,438)		3,167
Cash and cash equivalents beginning of period	55,010		61,958
Cash and cash equivalents end of period	$           37,572		$           65,125

 

Artivion, Inc. and Subsidiaries Financial Highlights In Thousands (Unaudited)
	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Products:
Aortic stent grafts	$             19,674		$             20,896		$             69,013		$             62,165
Surgical sealants	17,374		16,544		49,022		52,236
On-X	16,456		14,022		47,082		41,843
Other	1,744		1,645		6,609		6,284
Total products	55,248		53,107		171,726		162,528
Preservation services	21,590		19,100		62,665		56,914
Total revenues	$           76,838		$           72,207		$         234,391		$         219,442
Revenues:
US	$             41,250		$             36,205		$          119,938		$          111,529
International	35,588		36,002		114,453		107,913
Total revenues	$           76,838		$           72,207		$         234,391		$         219,442

 

Artivion, Inc. and Subsidiaries Reconciliation of GAAP to Non-GAAP Revenues and General, Administrative, and Marketing Expense In Thousands (Unaudited)
	Three Months Ended September 30,						Nine Months Ended September 30,
	2022		2021		Growth Rate		2022		2021		Growth Rate
Reconciliation of total revenues, GAAP to total revenues, non-GAAP:
Total revenues, GAAP	$   76,838		$    72,207		6 %		$  234,391		$  219,442		7 %
Impact of changes in currency exchange	—		(3,287)				—		(7,358)
Total constant currency revenue, non-GAAP	$   76,838		$    68,920		11 %		$  234,391		$  212,084		11 %

 

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Reconciliation of G&A expenses, GAAP to adjusted G&A, non-GAAP:
General, administrative, and marketing expense, GAAP	$            41,051		$            39,053		$          118,989		$          118,521
Corporate rebranding expense	251		461		1,423		523
Business development, integration, and severance expense (income)	864		1,309		(3,816)		6,138
Adjusted G&A, non-GAAP	$            39,936		$            37,283		$         121,382		$          111,860

 

Artivion, Inc. and Subsidiaries Reconciliation of GAAP to Non-GAAP Adjusted EBITDA In Thousands (Unaudited)
	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Reconciliation of net (loss) income, GAAP to adjusted EBITDA, non-GAAP:
Net (loss) income, GAAP	$        (13,713)		$         10,582		$        (21,361)		$            5,266
Adjustments:
Depreciation and amortization expense	5,519		6,009		17,016		18,008
Interest expense	4,805		4,100		12,854		12,995
Stock-based compensation expense	3,089		2,876		9,189		7,471
Loss on foreign currency revaluation	3,668		2,576		7,555		3,097
Clinical trial termination expense	4,741		—		4,741		—
Income tax expense (benefit)	1,181		(2,638)		3,100		(4,006)
Corporate rebranding expense	251		461		1,423		523
Gain from sale of non-financial assets	—		(15,923)		—		(15,923)
Interest income	(40)		(18)		(86)		(60)
Business development, integration, and severance expense (income)	864		1,309		(3,816)		6,138
Adjusted EBITDA, non-GAAP	$         10,365		$            9,334		$         30,615		$         33,509

 

Artivion Inc. and Subsidiaries Reconciliation of GAAP to Non-GAAP Net (Loss) Income and Diluted (Loss) Income Per Common Share In Thousands, Except Per Share Data (Unaudited)
	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
GAAP:
(Loss) income before income taxes	$            (12,532)		$               7,944		$            (18,261)		$               1,260
Income tax expense (benefit)	1,181		(2,638)		3,100		(4,006)
Net (loss) income	$            (13,713)		$             10,582		$            (21,361)		$               5,266
Diluted (loss) income per common share	$                (0.34)		$                 0.26		$                (0.53)		$                 0.13
Diluted weighted-average common shares outstanding	40,115		44,453		39,999		39,496
Reconciliation of (loss) income before income taxes, GAAP to    adjusted (loss) income, non-GAAP:
(Loss) income before income taxes, GAAP:	$            (12,532)		$               7,944		$            (18,261)		$               1,260
Adjustments:
Amortization expense	3,686		4,203		11,675		12,701
Clinical trial termination expense	4,741		—		4,741		—
Corporate rebranding expense	251		461		1,423		523
Non-cash interest expense	459		453		1,372		2,025
Gain from sale of non-financial assets	—		(15,923)		—		(15,923)
Business development, integration, and severance expense (income)	864		1,309		(3,816)		6,138
Adjusted (loss) income before income taxes, non-GAAP	(2,531)		(1,553)		(2,866)		6,724
Income tax (benefit) expense calculated at a pro forma tax rate of 25%	(633)		(388)		(717)		1,681
Adjusted net (loss) income, non-GAAP	$             (1,898)		$             (1,165)		$             (2,149)		$               5,043
Reconciliation of diluted (loss) income per common share, GAAP to    adjusted diluted (loss) income per common share, non-GAAP:
Diluted (loss) income per common share, GAAP:	$                (0.34)		$                 0.26		$                (0.53)		$                 0.13
Adjustments:
Amortization expense	0.09		0.11		0.29		0.33
Effect of 25% pro forma tax rate	0.10		(0.11)		0.19		(0.11)
Clinical trial termination expense	0.12		—		0.12		—
Non-cash interest expense	0.01		0.01		0.03		0.05
Corporate rebranding expense	—		0.01		0.03		0.01
Gain from sale of non-financial assets	—		(0.41)		—		(0.40)
Business development, integration, and severance expense (income)	0.03		0.04		(0.09)		0.15
Tax effect of non-GAAP adjustments	(0.06)		0.06		(0.09)		(0.03)
Adjusted diluted (loss) income per common share, non-GAAP	$               (0.05)		$                (0.03)		$               (0.05)		$                 0.13
Reconciliation of diluted weighted-average common shares outstanding    GAAP to diluted weighted-average common shares outstanding,    non-GAAP:
Diluted weighted-average common shares outstanding, GAAP:	40,115		44,453		39,999		39,496
Adjustments:
Effect of dilutive stock options and awards	—		(505)		—		—
Effect of convertible senior notes	—		(4,862)		—		—
Diluted weighted-average common shares outstanding, non-GAAP	40,115		39,086		39,999		39,496

 

Contacts:
Artivion	Gilmartin Group LLC
D. Ashley Lee	Brian Johnston / Lynn Lewis
Executive Vice President &	Phone: 332-895-3222
Chief Financial Officer	investors@artivion.com
Phone: 770-419-3355

View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-reports-third-quarter-2022-financial-results-301668265.html

SOURCE Artivion, Inc.

FAQ

What were Artivion's Q3 2022 financial results?

Artivion reported Q3 2022 revenue of $76.8 million, a 6% increase YoY on a GAAP basis, and a net loss of $13.7 million.

What is the revenue growth outlook for Artivion in 2022?

Artivion projects a constant currency revenue growth of 9% to 10% for the full year 2022, with expected revenues between $313.0 million and $316.0 million.

What were the main growth drivers for Artivion in Q3 2022?

The primary growth drivers included a 17% GAAP revenue increase in On-X products and significant international revenue growth of 25% in Asia Pacific.

Is Artivion anticipating any FDA approvals?

Yes, Artivion expects FDA PMA approvals for PROACT Mitral and PerClot by year end.

How did Artivion's expenses impact their net loss in Q3 2022?

Artivion's net loss included a $4.7 million charge related to the termination of the PROACT Xa study and pretax losses of $3.7 million due to foreign currency revaluation.